Company Description

Beech Biotech develops monoclonal antibodies engineered to remain in maternal circulation and avoid fetal exposure through patented modifications that block placental crossing. The company aims to treat maternal complications without exposing fetuses to therapeutic agents, addressing a key unmet need in pregnancy care.